Products

Online Inquiry

Name*

Phone

Email*

Services or Products of Interest*

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

β-TrCP (D12C8) Rabbit Antibody

INQUIRY

CAT. NO.: AMA-0697

Target Information
UniProt ID	Q9Y297

Product Details
Size	100 µL
Reactivity	Human, Mouse, Rat, Monkey
Host	Rabbit
Source/Isotype	Rabbit IgG
Storage	Store at -20°C. Do not aliquot the antibody.
Purification	Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to human β-TrCP protein.

Usage
Application	WB
Product Usage Information Dilution	Western Blotting (1:1000)
MW (Target)	62 kDa

Background
β-transducin repeat-containing protein (β-TrCP or FBW1A) is an F-box family protein characterized by the presence of the protein-protein mediating F-box domain first described in cyclin F. F-box proteins act as substrate adaptors that target proteins containing a specific phosphorylated sequence element, referred to as a phosphodegron, to the SCF E3 ubiquitin ligase complex for ubiquitination β-TrCP targets many important proteins with diverse functions, such as p53, H-Ras, Smad4, IκBα, β-catenin, and the cell cycle checkpoint protein claspin, for ubiquitin-mediated degradation Research studies have shown that inhibition of β-TrCP expression has a demonstrated benefit in the treatment of prostate cancer.

Background

β-transducin repeat-containing protein (β-TrCP or FBW1A) is an F-box family protein characterized by the presence of the protein-protein mediating F-box domain first described in cyclin F. F-box proteins act as substrate adaptors that target proteins containing a specific phosphorylated sequence element, referred to as a phosphodegron, to the SCF E3 ubiquitin ligase complex for ubiquitination β-TrCP targets many important proteins with diverse functions, such as p53, H-Ras, Smad4, IκBα, β-catenin, and the cell cycle checkpoint protein claspin, for ubiquitin-mediated degradation Research studies have shown that inhibition of β-TrCP expression has a demonstrated benefit in the treatment of prostate cancer.

Our customers have direct access to our experts and give timely feedback to any online inquiries. If you are interested in our products, please contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.